A Study to Determine the Immunogenicity and Oral Tolerance to Keyhole Limpet Hemocyanin (KLH)

This study has been terminated.
(Due to futility, identified after 5 subjects completed treatment in Part B)
Sponsor:
Collaborator:
Immune Tolerance Network (ITN)
Information provided by (Responsible Party):
National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier:
NCT01489956
First received: December 1, 2011
Last updated: December 20, 2013
Last verified: December 2013
  Purpose

The purpose of this study is to test the oral tolerance of Keyhole Limpet Hemocyanin (KLH) and to determine if Immucothel by itself is strong enough to trigger the immune response. If not, Immucothel will be tested in combination with an adjuvant to determine if an adequate immune response can be seen.


Condition Intervention Phase
Autoimmune Disorders
Biological: Subcutaneous Immucothel
Biological: Subcutaneous Immucothel plus Montanide
Biological: Oral KLH followed by immunization
Phase 0

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Pilot Study to Determine the Immunogenicity of Immucothel and Oral Tolerance Induction With Biosyn Native KLH in Healthy Subjects (ITN047AI)

Resource links provided by NLM:


Further study details as provided by National Institute of Allergy and Infectious Diseases (NIAID):

Primary Outcome Measures:
  • T cell stimulation index (SI) as measured by 3H-thymidine incorporation after in vitro KLH stimulation of PBMC (Part A) [ Time Frame: Day 0 ] [ Designated as safety issue: No ]
    An SI>=3 after the booster immunization, day 16, will indicate the presence of immune response

  • T cell stimulation index (SI) as measured by 3H-thymidine incorporation after in vitro KLH stimulation of PBMC (Part B) [ Time Frame: Day 42 ] [ Designated as safety issue: No ]
    An SI <3 after the booster immunization will indicated tolerance.

  • T cell stimulation index (SI) as measured by 3H-thymidine incorporation after in vitro KLH stimulation of PBMC (Part A) [ Time Frame: Day 9 ] [ Designated as safety issue: No ]
  • T cell stimulation index (SI) as measured by 3H-thymidine incorporation after in vitro KLH stimulation of PBMC (Part A) [ Time Frame: Day 16 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Cytokine secretion profile of T cells stimulated by KLH (Part A) [ Time Frame: Days 0, 9, 16 ] [ Designated as safety issue: No ]
  • T cell stimulation index measured by carboxyfluorescein diacetate succinimidyl ester (CFSE) staining after KLH stimulation. (Part A) [ Time Frame: Days 0, 9, 16 ] [ Designated as safety issue: No ]
  • Suppression (or non-activation) of cytokine secretion profile of T cells stimulated by KLH following oral feeding.(Part B) [ Time Frame: Day 42 ] [ Designated as safety issue: No ]
  • Suppression (or non-activation) of T cell stimulation index measured by CFSE staining after KLH stimulation.(Part B) [ Time Frame: Day 42 ] [ Designated as safety issue: No ]
  • Other mechanistic assessments on archived serum samples like anti-KLH antibodies and secreted cytokines.(Part B) [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  • Compare the level of KLH-specific antibodies in the serum (samples from various time points) between Parts A and B. [ Time Frame: 6 months ] [ Designated as safety issue: No ]

Enrollment: 19
Study Start Date: December 2011
Study Completion Date: April 2013
Primary Completion Date: April 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: SQ Immucothel alone (Part A) Biological: Subcutaneous Immucothel
100 ug at day 0 (priming dose) and day 9(booster dose)
Experimental: SQ Immucothel + Montanide (Part A) Biological: Subcutaneous Immucothel plus Montanide
100 ug SQ Immunoclthel plus Montanide at day 0 (priming dose) and day 9 (booster dose)
Experimental: Either Immucothel alone or Immucothel with Montanide. (Part B)
Dependent on the results for Part A
Biological: Oral KLH followed by immunization
50 mg of native KLH on days 0-4 and 10-14 (total of 500 mg). Immunization on days 26 and 35.

Detailed Description:

One type of normal immune response is called "oral tolerance." This is when the immune system (the body's natural defense system against illness) turns off (e.g. does not respond) to foods or to other proteins that are eaten. Oral tolerance test is done by feeding people a protein and then vaccinating them with the same protein. Oral tolerance occurs if the vaccination does not cause an immune response.

In this study, oral tolerance of Keyhole Limpet Hemocyanin (KLH) will be tested. KLH is a large protein extracted from a mollusk (a sea animal). The 'native KLH' (which is a large version of this protein) formulation will be used for oral feeding. Immucothel (a smaller version of the KLH protein) will be used for vaccination (injection). Immucothel is an investigational vaccine currently used to treat bladder cancers outside of the US.

Since these particular KLH products have never been used in oral tolerance studies, the investigators want to make sure in this pilot study that they will work as expected in healthy participants before studying these two products in patients with auto-immune disorders.

This study will also determine if Immucothel by itself is strong enough to trigger the immune response. If not, Immucothel will be tested in combination with an adjuvant (a substance that can increase the immune response to a protein like KLH) to determine if an adequate immune response can be seen.

This study consists of two parts. Participants will participate for either 39 days (Part A) or 65 days (Part B). Regardless of the group assignment, a safety follow-up phone call will occur 6 months after the last immunization (189 day for Part A or 215 day for part B) to assess the late onset of adverse events.

Part A of the study will test the experimental vaccine Immucothel by itself or in combination with an adjuvant. Immucothel is a purified protein from a mollusk. Immucothel can be given as a sub-q injection (under the skin) alone or with an adjuvant (a small amount of mineral oil) to help to enhance the immune response. There maybe two groups in this part:

  1. Ten evaluable (as defined by protocol) participants will be given Immucothel alone by injection on two occasions, If Immucothel alone creates an immune response in most of the participants then Part A will be completed.
  2. If Immucothel alone does not create an immune response in most of the participants in Part A, then 10 new evaluable (as defined by protocol) participants will be asked to volunteer to test Immucothel in combination with the adjuvant Montanide (mineral oil). This will be given by injection on two occasions If there is an immune response in most of the participants to this combination of Immucothel and Montanide then Part A will be done.

Part B of the study will test the successful Immucothel regimen from Part A with oral KLH. Ten new evaluable (as defined by protocol) participants will be given the experimental oral KLH.

  Eligibility

Ages Eligible for Study:   18 Years to 50 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy
  • Ability to give informed consent and comply with study procedures.
  • Participant able/willing to hold off receiving prophylactic immunizations (like influenza or pneumococcal vaccines) during the study period.

Exclusion Criteria:

  • Use of corticosteroids within 2 weeks prior to screening visit.
  • First degree relative (parent, sibling or child) with history of autoimmune disease.
  • Presence of chronic medical illness including but not limited to chronic kidney-, liver-, cardio-vascular diseases, immunodeficiencies, anemia, B12 deficiency, malignancies, or chronic active infections.
  • History of acute gastrointestinal illness within 2 weeks prior to oral KLH administration.
  • For women of child bearing age, participant unwilling to defer pregnancy, has a positive urine pregnancy test or is currently pregnant or lactating.
  • Use of an investigational drug within 3 months of the screening visit.
  • History of acute febrile illness within 1 week of screening visit.
  • History of allergy to shellfish, previous exposure to KLH/product containing KLH or known-sensitivity to KLH / components of KLH preparation.
  • Participants receiving any immunizations within 1 month prior to screening visit.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01489956

Locations
United States, New York
Mount Sinai Medical Center
New York, New York, United States, 10029
Sponsors and Collaborators
Immune Tolerance Network (ITN)
Investigators
Study Chair: Lloyd Mayer, MD Mount Sinai School of Medicine
  More Information

Additional Information:
No publications provided

Responsible Party: National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier: NCT01489956     History of Changes
Other Study ID Numbers: DAIT ITN047AI
Study First Received: December 1, 2011
Last Updated: December 20, 2013
Health Authority: United States: Food and Drug Administration
United States: Federal Government

Keywords provided by National Institute of Allergy and Infectious Diseases (NIAID):
Keyhole Limpet Hemocyanin (KLH)
Immucothel
Native KLH
Healthy volunteers
Oral tolerance
Immunogenicity
Autoimmune diseases

Additional relevant MeSH terms:
Autoimmune Diseases
Immune System Diseases
Keyhole-limpet hemocyanin
Adjuvants, Immunologic
Immunologic Factors
Physiological Effects of Drugs
Pharmacologic Actions

ClinicalTrials.gov processed this record on August 20, 2014